Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke

TARDIS (ISRCTN47823388)

The 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial is a collaborative, international, multicentre, prospective, randomised, blinded endpoint, parallel-group, controlled trial testing the safety and efficacy of one month of intensive antiplatelet therapy (combined aspirin, clopidogrel and dipyridamole) in comparison with guideline antiplatelet therapy (aspirin and dipyridamole) in patients with acute ischaemic stroke or TIA

4,100+ patients with acute ischaemic stroke or high risk TIA are enrolled within 48 hours of onset. The primary outcome is the frequency and severity of recurrent cerebrovascular events determined at 90 days by observers blinded to treatment. The BHF-funded start-up phase tested the safety, feasibility and tolerability of the trial and interventions. The main phase of the trial is funded by the HTA.

If you are interested in having your centre join the trial, please fill in an Expression of Interest form and send/fax to the Coordinating Centre as per details at bottom of form.

Trial synopsis, V1.0 (pdf)


2014, August: Congratulations to all recruiting sites and investigators: we have reached our 2000th participant! Please continue to consider all ischaemic stroke and TIA patients for inclusion.

TARDIS trial website and database

Enter LIVE TARDIS trial web-site


Status

As of 26th August 2014 (see logon page for latest numbers):

Enrolled patients: 2026 - ischaemic stroke 1345 (66.4%), TIA 681 (33.6%)
Guideline split in stroke: Clopidogrel 46.7%, aspirin/dipyridamole 53.3%
Guideline split in TIA: Clopidogrel 36.5%, aspirin/dipyridamole 63.5%
Centres in the UK: 117 Centres in Europe: 6 Centres in Oceania: 1 Total centres: 124


Tweets by @tardistrial

Funding


Forthcoming events

TARDIS will be attending:

News


TARDIS in the News

TARDIS trial seeks new dimension in stroke treatment Medical Xpress, 17 Oct 2011
TARDIS trial seeks new dimension in stroke treatment HealthCanal, 17 Oct 2011
TARDIS trial seeks new dimension in stroke treatment University of Nottingham, 17 Oct 2011
Triple cocktail to tackle stroke risk Physorg.com, 17 Sept 2008

Documents

Newsletter 14 - July 2014 (pdf) **NEW**
Newsletter 13 - January 2014 (pdf)
Newsletter 12 - November 2013 (pdf)
Newsletter 11 - July 2013 (pdf)
Newsletter 10 - March 2013 (pdf)
Newsletter 9 - July 2012 (pdf)
Newsletter 8 - January 2012 (pdf)
Newsletter 7 - October 2011 (pdf)
Newsletter 6 - August 2011 (pdf)
Newsletter 5 - April 2011 (pdf)
Newsletter 4 - December 2010 (pdf)
Newsletter 3 - August 2010 (pdf)
Newsletter 2 - April 2010 (pdf)
Newsletter 1 - December 2009 (pdf)


Presentations/publications/listings/media


Demo/practice website and database

Enter DEMO TARDIS demonstration/practice trial web-site


Study personnel

Trial Steering Committee:
Helen Rodgers (Newcastle, Independent Chair/Stroke Physician), Philip Bath (Nottingham, Chief Investigator/Stroke Physician), Rob Dineen (Nottingham, Neuroradiologist), Lelia Duley (Nottingham, Trialist), Ahamad Hassan (Leeds, Independent Neurologist), Stan Heptinstall (Nottingham, Platelets), Marilyn James (Nottingham, Health Economics), Hugh Markus (London, Neurologist), Chibeka Kasonde (Nottingham, Participant representative/Independent member), Stuart Pocock (London, Biostatistician), Tom Robinson (Leicester, Stroke Physician), Christine Roffe (Stoke-on-Trent, Independent Expert/Stroke Physician), Craig Smith (Salford, Independent Stroke Physician), Niki Sprigg (Nottingham, Co-Chief Investigator), Graham Venables (Sheffield, Neurologist), Angela Shone (University of Nottingham, Sponsor representative), William Toff (Leicester, Independent Trialist)

International Advisory Committee:
Denmark - Hanne Christensen, Georgia - Maia Beridze, New Zealand - Anna Ranta

Trial Management Committee (Nottingham):
Philip Bath (Chair), Sally Utton (Trial Manager), Hayley Foster (Assistant Trial Manager), Margaret Adrian (UK Trial Coordinator: North), Tanya Payne (UK Trial Coordinator: South), Harriet Howard (UK Trial Coordinator), Michael Stringer (UK Trial Coordinator), Sarah Grant (International Trial Coordinator), Alice Durham (International Trial Coordinator), Joanne Keeling (Outcome Coordinator), Kailash Krishnan (Medic), Katie Robson (Statistician), Dawn Hazle (Data and Imaging), Wim Clarke (Financial), Yvonne Smallwood (Secretary), Lauren Dunn (Secretary)

Independent Data Monitoring Committee:
Ian Ford (Glasgow, Chair), Cathie Sudlow (Edinburgh), Matthew Walters (Glasgow), Katie Robson (Statistician, Nottingham)

Independent Events (outcome, SAE) Adjudicator:
Nikola Sprigg (Nottingham), Tim England (Derby)

Neuroimaging Adjudicators:
Rob Dineen (Nottingham), Alessandro Adami (Verona, Italy), Jennifer Becker (Arizona, USA), Lesley Cala (Perth, Australia), Ana Casado (Edinburgh, UK)

Platelet substudy:
Stan Heptinstall, Sue Fox, Jane May (Nottingham)

Programming/database management:
Richard Dooley, Liz Walker (UK)


Contact details

TARDIS Trial Office
Stroke, Division of Clinical Neuroscience
University of Nottingham
Clinical Sciences Building
City Hospital Campus
Hucknall Road
Nottingham
NG5 1PB
UK
 
Telephone: +44 115 823 1770
Fax: +44 115 823 1771
E-mail: tardis@nottingham.ac.uk

Written by Philip Bath, last updated by Dawn Hazle 26th August 2014

Valid HTML 4.01 Transitional